Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner

Women's Health

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

Age, fertility status, and other factors influence satisfaction with progestin treatment for abnormal uterine bleeding

Doctors have been unable to reach a consensus on the type of medical management indicated for various types of abnormal uterine bleeding or when surgery should be considered for the problem. Progestins are considered one of the primary treatments for abnormal uterine bleeding. However, a woman's satisfaction with progestin treatment depends on her age, fertility status, attitudes about uterine conservation, and intensity of desire to resolve the bleeding, finds a study supported by the Agency for Healthcare Research and Quality (HS09478).

Doctors should consider not only the type and severity of uterine bleeding and associated symptoms, but also whether this therapy is in line with a woman's treatment expectations, future reproductive plans, and beliefs about her cycle, suggests lead author, Holly E. Richter, Ph.D., M.D., of the University of Alabama at Birmingham. Dr. Richter and her colleagues studied 413 premenopausal women 30 years of age or older who had abnormal uterine bleeding, with or without fibroids, who were treated for 3 to 5 months with oral medroxyprogesterone acetate (MPA) at 10 to 20 mg per day for 10 to 14 days per month. They assessed the women's satisfaction with and willingness to continue MPA and examined sociodemographic, clinical, and other factors that might predict satisfaction.

Over half (57 percent) of the women who completed the survey said they were satisfied with MPA for control of bleeding. These women were more likely than dissatisfied women to report improvement in bleeding (100 vs. 29 percent), less likely to report bothersome side effects (4 vs. 31 percent), and more likely to express a strong preference for medical treatment over a hysterectomy (70 vs. 26 percent). Women aged 35 or older were nearly three times as likely to be satisfied with MPA as women aged 30 to 35. Those who wanted to conserve their uterus were 36 percent more likely to be satisfied with the treatment, while those who viewed cessation of bleeding as important and who had undergone tubal sterilization were less likely to be satisfied.

More details are in "Medroxyprogesterone acetate treatment of abnormal uterine bleeding: Factors predicting satisfaction," by Dr. Richter, Lee A. Learman, M.D., Ph.D., Feng Lin, M.S., and others, in the July 2003 American Journal of Obstetrics & Gynecology 189, pp. 37-42.

Return to Contents
Proceed to Next Article

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care